Miscellaneous Neoplasm - Solid Tumor

NCT04439175

Clinical Trial Information


Trial Number: NCT04439175 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA mutation but without KRAS mutation or PTEN loss
Study ID:
EAY131-I
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439201

Clinical Trial Information


Trial Number: NCT04439201 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification
Study ID:
EAY131-Z1B
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439136

Clinical Trial Information


Trial Number: NCT04439136 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations
Study ID:
EAY131-B
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT03578081

Clinical Trial Information


Trial Number: NCT03578081 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Miscellaneous Neoplasm - Carcinoma, Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
OLANZAPINE WITH OR WITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Study ID:
A221602
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439357

Clinical Trial Information


Trial Number: NCT04439357 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations
Study ID:
EAY131-S2
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439318

Clinical Trial Information


Trial Number: NCT04439318 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients With Tumors With NF1 Mutations
Study ID:
EAY131-S1
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04387656

Clinical Trial Information


Trial Number: NCT04387656 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Leukemia - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Study ID:
NCICOVID
Images are available?:
No
Is this a NCI-MATCH Trial?:
No


Datasets Linked to Trial

Title Description
NCT04387656-D1 This dataset contains information used in the analyses described and presented in “COVID-19 severity by vaccination status in patients enrolled to the National Cancer Institute COVID-19 and Cancer Patients Study (NCCAPS)”, including the erratum.
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). Data presented in Figure 1 in the publication are not contained within this data submission, and data presented in Figure 2 have been modified due to de-identification procedures. Specifically, dates of study enrollment and first positive SARS-CoV-2 test have been omitted and year of first positive SARS-CoV-2 test has been substituted for time period of first positive SARS-CoV-2 test.

NCT04439253

Clinical Trial Information


Trial Number: NCT04439253 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients With ROS1 Translocations (Other Than Patients With Non-Small Cell Lung Cancer)
Study ID:
EAY131-G
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439266

Clinical Trial Information


Trial Number: NCT04439266 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol F: Crizotinib in Patients With Tumors (Other Than Adenocarcinoma of Lung or ALCL) With ALK Rearrangements
Study ID:
EAY131-F
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439123

Clinical Trial Information


Trial Number: NCT04439123 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Hematopoietic Neoplasm/Myeloma - Myeloma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations
Study ID:
EAY131-Y
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Subscribe to Miscellaneous Neoplasm - Solid Tumor

Accessibility  |  Disclaimer  |  FOIA  |  HHS Vulnerability Disclosure  |  Privacy & Security

U.S. Department of Health and Human Services  |  National Institutes of Health  |  National Cancer Institute  |  USA.gov

NIH…Turning Discovery Into Health®